Lung cancer patients with minimally invasive adenocarcinoma have similar, positive five-year disease-free survival (DFS) and overall survival (OS) rates as patients with adenocarcinoma in-situ.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now